MyndTec Inc. announced that it has received from the U.S. Food and Drug Administration (the "FDA") 510(k) clearance for MyndMove 2.0, its second generation neuromodulation MyndMove System. The MyndMove System is a touch screen, eight-channel neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following stroke or spinal cord injury. The MyndMove System includes a stimulator unit, electrodes, hand and foot switches, an optional cart, and integrated software that allows the user to choose from a number of pre-programmed stimulation protocols, to customize the stimulation intensities for each patient and document the treatments provided.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.75 CAD | -.--% | -.--% | +50.00% |
2023 | MyndTec Inc. announced that it has received CAD 0.13821 million in funding | CI |
2023 | MyndTec Inc. announced that it expects to receive CAD 1.033578 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+50.00% | 13.19M | |
+7.77% | 218B | |
+10.16% | 189B | |
+26.21% | 151B | |
+32.78% | 113B | |
+1.98% | 64.02B | |
+14.48% | 52.6B | |
+2.92% | 49.85B | |
-6.60% | 37.89B | |
-1.07% | 34.92B |
- Stock Market
- Equities
- MYTC Stock
- News MyndTec Inc.
- Myndtec Inc. Receives Fda 510(K) Clearance for Myndmove 2.0, Its Second Generation Neuromodulation Device, for Clinical and Home Use